CEO INVESTOR CONFERENCE February 13-14, 2017 • The Waldorf Astoria New York bio.org/CEO • #BIOCEO16 bio.org/CEO • #BIOCEO17 CEO INVESTOR CONFERENCE Now in its 19th year, the BIO CEO & Investor Conference WHY ATTEND? is one of the largest investor • EXPERIENCE the largest, unbiased forum where institutional conferences focused on investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry. established and emerging publicly traded and select • HEAR Washington’s perspective on how the Trump Administration will address ACA, CMS and PDUFA VI. private biotech companies. • EVALUATE fresh investment opportunities including compatible, complementary and competitive companies. • LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. • ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2017. • GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event. • HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. • GET THE PULSE of the current and proposed investment trends in biotechnology. • NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions. 2 bio.org/CEO CEO INVESTOR CONFERENCE 2017 FIRESIDE CHAT SPEAKERS Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company Giovanni Caforio, MD Tony Coles, MD President and Chief Chairman and Chief successes, what keeps the Executive Officer, Executive Officer, C-suite up at night, and Bristol-Myers Squibb Yumanity Therapeutics where the industry’s leading companies are headed in 2017. Jeffrey D. Marrazzo J. Joseph Kim, PhD Co-Founder and Chief President and Chief Executive Officer, Executive Officer, Spark Therapeutics Inovio Pharmaceuticals Lynn Seely, MD Chief Executive Officer, Myovant Sciences #BIOCEO17 3 2017 AGENDA APPLYING MICROBIOME RESEARCH MODERATOR: Michael King, Managing Director and Senior TO THERAPEUTICS Research Analyst, JMP Securities Monday • February 13, 2017 • 9:00 am – 9:55 am SPEAKERS Joseph Pearlberg, MD, Vice President Clinical Development, Infinity Pharmaceuticals, Inc. New discoveries are finding links that extend significantly beyond the gut microbiome and intestinal disorders into a range Jerome Zeldis, MD, PhD, Chief Medical Officer of bodily systems including the immune and nervous systems. and President of Clinical Development, Sorrento Major biopharma companies have engaged in significant deals Therapeutics that envision treatments to commercialize from this research and leading companies are pushing forward on clinical trials. NEXT GENERATION PAIN CONTROL: This session will outline the microbiome influenced therapies BEYOND OPIOIDS most likely to create major effects for patients. Monday • February 13, 2017 • 1:30 pm – 2:25 pm MODERATOR: C. Simone Fishburn, PhD, Editor, The scourge of rising addiction and heroin overdoses has BioCentury Innovations been associated with the growth in usage of important, opioid- SPEAKERS Pierre Belichard, PharmD, PhD, Chief based, prescription pain treatments. New approaches to pain Executive Officer, Enterome control are looking at different biological mechanisms and Mark Bodmer, PhD, Chief Scientific Officer, methodologies for improving patients’ lives with lower risks Evelo Biosciences of ill effects or addiction. This session will speak with experts developing therapeutic innovations that do not rely on opioid- Board of Directors, Nick Conley, PhD, based drugs and can provide doctors additional alternatives for Co-founder & Chief Executive Officer, EpiBiome helping patients. JC Gutiérrez-Ramos, PhD, Chief Executive Officer, Synlogic MODERATOR: Corey Davis, PhD, Managing Director, Senior Jeffrey Riley, Chief Executive Officer, President Healthcare Analyst, H.C. Wainwright & Co., LLC and Director, Synthetic Biologics SPEAKERS Gail Cawkwell, MD, Chief Medical Officer, Nancy Thornberry, Chief Executive Officer, Purdue Pharma L.P. Kallyope (invited) Derek Chalmers, PhD, DSc, Chief Executive Nikola Trbovic, PhD, Director R&D Technology Officer, President, and Director, Cara Therapeutics Strategy, Worldwide Research & Development, Russell Herndon, President and Chief Pfizer Inc. Executive Officer, Hydra Biosciences Jeffrey B. Kindler, Chief Executive Officer, Centrexion Therapeutics FIRESIDE CHAT WITH J. JOSEPH KIM, PHD President and Chief Executive Officer, Gerhard Koenig, PhD, Chief Executive Officer, Inovio Pharmaceuticals Quartet Medicine, Inc. Monday • February 13, 2017 • 10:00 am – 10:55 am MODERATOR Phyllis A. Arthur, Managing Director, FIRESIDE CHAT WITH TONY COLES, MD Infectious Diseases and Diagnostics Policy, Biotechnology Chairman and Chief Executive Officer, Yumanity Therapeutics Innovation Organization Monday • February 13, 2017 • 2:30 pm – 3:25 pm MODERATOR Ian Woo, Managing Director, Lazard CAR-T, TILS, AND BISPECIFICS: IMMUNO- ONCOLOGY CHALLENGES AND OPPORTUNITIES Monday • February 13, 2017 • 11:00 am – 11:55 am IPOS AND BEYOND: TAPPING INTO THE PUBLIC The maturation of new cancer treatment technologies has MARKET’S CAPITAL produced a mix of highly positive patient outcomes and some Monday • February 13, 2017 • 3:30 pm – 4:25 pm serious clinical holds, while investments for manufacturing and As biotech IPO activity has cooled from its 2015 peak, commercialization continue to accelerate. This session will dive companies are more deliberately weighing reverse mergers into the assumptions underlying the most aggressive approaches and other alternatives to benefiting from the capital in public and the ways of reducing the risks of failure along the way to markets. With post-election market uncertainty, does the IPO delivering immuno-oncology’s promise to patients broadly. market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices? *Speakers added daily 4 bio.org/CEO CEO INVESTOR CONFERENCE This session will feature experienced voices for explaining the EMBEDDING DIVERSITY INTO BOARD AND practical techniques for getting into public markets and what EXECUTIVE TEAM RECRUITMENT investors are expecting to see in order to win their support. Tuesday • February 14, 2017 • 10:00 am – 10:55 am MODERATOR Stephen B. Thau, Partner, Morrison & The biopharma industry has seen enormous growth in recent Foerster LLP years of the number of start-ups and IPOs, with hundreds of SPEAKERS James Cappuccio, Managing Director, new executive team and board member positions being filled. Investment Banking, H.C. Wainwright & Co., LLC However, the inclusion of underrepresented groups in these Brian Hagerty, Senior Director, Head of influential positions has failed to keep pace with the growth of Healthcare Capital Markets, New York biopharma companies and too often the decision-makers fail Stock Exchange to reflect the employee bases they lead or patient populations Douglas E. Onsi, Chief Financial Officer, they serve. This session will focus on practical approaches and Leap Therapeutics, Inc. successful examples to improve the diversity of leadership recruitment efforts and better align organizations with the full Sapna Srivastava, PhD, former Chief Financial measure of talented people available. Officer and Chief Strategy Officer, Intellia Therapeutics MODERATOR Julie L. Gerberding, MD, MPH, Executive Vice Nassim Usman, PhD, President and Chief President & Chief Patient Officer, Strategic Executive Officer, Catalyst Biosciences Communications, Global Public Policy and Population Health, Merck SPEAKERS Colleen Cuffaro, PhD, Principal, Canaan FIRESIDE CHAT WITH LYNN SEELY, MD President and Chief Executive Officer, Myovant Sciences Partners Paul J. Hastings, Chairman and Chief Executive Monday • February 13, 2017 • 4:30 pm – 5:25 pm Officer, OncoMed Pharmaceuticals MODERATOR K.C. Stone, Managing Director, Head of Dawn Hocevar, President, Women in Bio Healthcare Investment Banking, BTIG Stephen M. Ritoch, Chairman of the Board and Chief Executive Officer, Blaise Group LIVING WITH BIOSIMILARS: STRATEGY FORMULATION AND LESSONS FROM FIRESIDE CHAT WITH JEFFREY D. MARRAZZO, OTHER MARKETS Co-Founder and Chief Executive Officer, Spark Therapeutics Tuesday • February 14, 2017 • 9:00 am – 9:55 am Tuesday • February 14, 2017 • 12:00 pm – 12:55 pm As biosimilar medicine options begin to roll-out in the United States, the regulatory and legal uncertainties are also starting MODERATOR Erin McCallister, Senior Editor, BioCentury to shrink below the market adoption uncertainties. As some Publications innovator companies also pursue biosimilar development, and others seek to compete, there are opportunities to learn from jurisdictions that have allowed biosimilar medicines for longer POLICY OUTLOOK—ACA, CMS, PDUFA VI AND periods, such as Japan and Europe regarding the reactions THE TRUMP ADMINISTRATION of doctors and payers. This session will feature executives Tuesday • February 14, 2017 • 12:30 pm – 1:25 pm from innovator companies explaining how they evaluate biosimilars within their pipelines, plus those with expertise on From a healthcare policy point of view, 2017